FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

CBER File Over Protest SOPP

[ Price : $8.95]

CBER publishes a Standard Operating Policy and Procedure on filing an application over protest after a Center refusal-to-file deci...

FDA Expanding Real-World Evidence Use in Device Regulation

[ Price : $8.95]

CDRH leaders describe efforts to expand the use of real-world evidence in a range of medical device regulatory activities.

FDA Enforcement Discretion for Some Hemp CBD Products

[ Price : $8.95]

FDA says it will exercise enforcement discretion and not enforce specific sections of the Federal Food, Drug, and Cosmetic Act as ...

Trump Plans New Tariffs on Pharmaceutical Industry

[ Price : $8.95]

President Trump prepares to impose sweeping new tariffs on certain pharmaceutical imports, targeting companies that have not agree...

FDA Denies CAD/CADt Device 510(k) Exemption Petition

[ Price : $8.95]

FDA denies a petition seeking a partial exemption of 510(k) requirements for some specific radiology computer-aided detection and/...

Bipartisan Senators Urge FDA to Pre-Screen Certain Drug Ads

[ Price : $8.95]

Two bipartisan senators press FDA to take a more proactive role in policing prescription drug advertising, citing a surge in misle...

FDA Accepts Ultragenyx Resubmission for Gene Therapy

[ Price : $8.95]

Ultragenyx Pharmaceutical refiles a BLA seeking accelerated approval for UX111, an AAV9 gene therapy for the treatment of Sanfilip...

Makary Signals Push for Faster Approvals, and Sweeping Reforms

[ Price : $8.95]

In a wide-ranging 4/1 address to employees at FDA, commissioner Marty Makary outlines an expansive agenda to accelerate drug appro...

Kites Tecartus for Mantle Cell Lymphoma Gets Full Approval

[ Price : $8.95]

FDA grants full approval for Kites CAR-T cell therapy Tecartus (brexucabtagene autoleucel) for adult patients with relapsed or ref...

New CBER Head Should Restore Rare Disease Clarity: Advocates

[ Price : $8.95]

A rare disease coalition calls on the Trump administration to appoint a new CBER director who understands rare disease drug develo...